Seminars in Oncology
Volume 33 , Pages 17-20 , February 2006

Combination Treatment Modalities in Cutaneous T-Cell Lymphoma (CTCL)

  • Joan Guitart

      Affiliations

    • Corresponding Author InformationAddress correspondence and reprint requests to Joan Guitart, MD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, NMH/Galter Room 19−150, 675 North St Clair, Chicago, IL 60611

References 

  1. Zackheim HS , Kashani-Sabet M , Amin S . Topical corticosteroids for mycosis fungoides (Experience in 79 patients) . Arch Dermatol . 1998;34:949–954
  2. Kim YH , Martinez G , Varghese A , et al.   Topical nitrogen mustard in the management of mycosis fungoides (Update of the Stanford experience) . Arch Dermatol . 2003;139:165–173
  3. de Quatrebarbes J , Esteve E , Bagot M , et al.   Treatment of early stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids . Arch Dermatol . 2005;141:1117–1120
  4. Apisarnthanarax N , Talpur R , Ward S , et al.   Tazarotene 0.1% gel for refractory mycosis fungoides lesions (an open-label pilot study) . J Am Acad Dermatol . 2004;50:600–607
  5. Breneman D , Duvic M , Kuzel T , et al.   Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma . Arch Dermatol . 2002;138:325–332
  6. Suchin KR , Cucchiara AJ , Gottleib SL , et al.   Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy (A 14-year experience at a single institution) . Arch Dermatol . 2002;138:1054–1060
  7. Kuzel TM , Roenigk HH , Samuelson E , et al.   Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome . J Clin Oncol . 1995;13:257–263
  8. Chiarion-Sileni V , Bononi A , Fornasa CV , et al.   Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma . Cancer . 2002;95:569–575
  9. Thomsen K , Hammar H , Molin L , et al.   Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage (A report from the Scandinavian Mycosis Fungoides Group) . Acta Derm Venereol . 1989;69:536–538
  10. Duvic M , Martin AG , Kim Y , et al.   Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma . Arch Dermatol . 2001;137:581–593
  11. Duvic M , Hymes K , Heald P , et al.   Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma (Multinational phase II-III trial results) . J Clin Oncol . 2001;19:2456–2471
  12. Talpur R , Ward S , Apisarnthanarax N , et al.   Optimizing bexarotene therapy for cutaneous T-cell lymphoma . J Am Acad Dermatol . 2002;47:672–684
  13. Singh F , Lebwohl MG . Cutaneous T-cell lymphoma treatment using bexarotene and PUVA (A case series) . J Am Acad Dermatol . 2004;51:570–573
  14. Heald P , Mehlmauer M , Martin AG , et al.   Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma (Results of the phase III clinical trial) . J Am Acad Dermatol . 2003;49:801–815
  15. Stern DK , Lebwohl M . Treatment of mycosis fungoides with oral bexarotene combined with PUVA . J Drugs Dermatol . 2002;1:134–136
  16. McGinnis KS , Shapiro M , Vittorio CC , et al.   Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy (An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma) . Arch Dermatol . 2003;139:771–775
  17. Hermann KK , Roenigk HH , Hurria A , et al.   Treatment of mycosis fungoides with photochemotherapy (PUVA) (Long-term follow-up) . J Am Acad Dermatol . 1995;33:234–242
  18. French LE , Shapiro M , Junkins-Hopkins JM , et al.   Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy . J Am Acad Dermatol . 2001;45:914–918
  19. McGinnis KS , Junkins-Hopkins JM , Crawford G , et al.   Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma (Clinical synergism and possible immunologic mechanisms) . J Am Acad Dermatol . 2004;50:375–379

 This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.

 Dr Guitart is a member of the speakers bureau for Ligand Pharmaceutical.

PII: S0093-7754(05)00512-9

doi: 10.1053/j.seminoncol.2005.12.018

Seminars in Oncology
Volume 33 , Pages 17-20 , February 2006

Article Tools